Oncotarget

Corrections:

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

José Luis Ordóñez _, Ana Teresa Amaral, Angel M. Carcaboso, David Herrero-Martín, María del Carmen García-Macías, Vicky Sevillano, Diego Alonso, Guillem Pascual-Pasto, Laura San-Segundo, Monica Vila-Ubach, Telmo Rodrigues, Susana Fraile, Cristina Teodosio, Agustín Mayo-Iscar, Miguel Aracil, Carlos María Galmarini, Oscar M. Tirado, Jaume Mora and Enrique de Álava

PDF

Oncotarget. 2017; 8:43592-43592. https://doi.org/10.18632/oncotarget.18610

Metrics: PDF 818 views  |   ?  

Present: The published funding information is incomplete.

Corrected: Additional funding information is given below.

FUNDING

This work was supported by Menarini Spain, grants PI 15/00598 from Fondo de Investigaciones Sanitarias (FIS) Carlos III Institute to A.A .; SAF2013-47611R from The Ministry of Economy and Competitiveness and grant S2010 / BMD-2321 (FIBROTEAM Consortium) from Autonomous Community of Madrid to M.L.-C .; G.L. Was Fully supported from theEuropean ETRiPD Marie Curie Project.

Original article: Oncotarget. 2015; 6:18875-90. DOI:10.18632/oncotarget.4303.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18610